{"abstract": "With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson.", "web_url": "https://www.nytimes.com/2015/03/06/business/dealbook/why-abbvie-may-have-overpaid.html", "snippet": "With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson.", "lead_paragraph": "AbbVie\u2019s chief executive may have overpaid once again.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Why AbbVie May Have Overpaid for Cancer Drug Maker", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Biotechnology and Bioengineering", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pharmacyclics, Incorporated", "rank": 4, "major": "N"}, {"name": "organizations", "value": "AbbVie Inc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Shire PLC", "rank": 7, "major": "N"}], "pub_date": "2015-03-05T20:23:36+0000", "document_type": "article", "news_desk": "Dealbook", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/0489cc36-72af-5e00-b03e-5a0be61145d0", "word_count": 378, "uri": "nyt://article/0489cc36-72af-5e00-b03e-5a0be61145d0"}